EP4011865A4 - Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof - Google Patents

Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof Download PDF

Info

Publication number
EP4011865A4
EP4011865A4 EP20851903.3A EP20851903A EP4011865A4 EP 4011865 A4 EP4011865 A4 EP 4011865A4 EP 20851903 A EP20851903 A EP 20851903A EP 4011865 A4 EP4011865 A4 EP 4011865A4
Authority
EP
European Patent Office
Prior art keywords
preparation
method therefor
pharmaceutical use
pyrimidine compound
substituted pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20851903.3A
Other languages
German (de)
French (fr)
Other versions
EP4011865A1 (en
Inventor
Huijun YIN
Xu YAN
Jizhou SHI
Guobiao LIU
Teng FEI
Liuxin DONG
Yuanye LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of EP4011865A1 publication Critical patent/EP4011865A1/en
Publication of EP4011865A4 publication Critical patent/EP4011865A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP20851903.3A 2019-08-09 2020-08-05 Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof Pending EP4011865A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910733723 2019-08-09
PCT/CN2020/107054 WO2021027647A1 (en) 2019-08-09 2020-08-05 Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
EP4011865A1 EP4011865A1 (en) 2022-06-15
EP4011865A4 true EP4011865A4 (en) 2022-11-02

Family

ID=74570903

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20851903.3A Pending EP4011865A4 (en) 2019-08-09 2020-08-05 Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof

Country Status (8)

Country Link
US (1) US20220348572A1 (en)
EP (1) EP4011865A4 (en)
JP (1) JP2022543690A (en)
KR (1) KR20220046593A (en)
CN (1) CN112654605B (en)
AU (1) AU2020328707A1 (en)
CA (1) CA3144420A1 (en)
WO (1) WO2021027647A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4279485A1 (en) * 2021-01-14 2023-11-22 The National Institutes of Pharmaceutical R&D Co., Ltd Bridged heterocyclyl-substituted pyrimidine compounds, preparation method and medical use thereof
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160052930A1 (en) * 2014-08-21 2016-02-25 Pfizer Inc. Aminopyrimidinyl compounds
CN110862376A (en) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 Small molecule compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638018A1 (en) * 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
KR20160046917A (en) * 2013-09-03 2016-04-29 카나 바이오사이언스, 인코포레이션 Novel 2,6-diaminopyrimidine derivative
WO2017035366A1 (en) * 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160052930A1 (en) * 2014-08-21 2016-02-25 Pfizer Inc. Aminopyrimidinyl compounds
CN110862376A (en) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 Small molecule compound
WO2021078021A1 (en) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 Small molecular compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FENSOME ET AL.: "Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)", J. MED. CHEM., vol. 61, no. 19, 11 October 2018 (2018-10-11), US, pages 8597 - 8612, XP055688622, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00917 *
See also references of WO2021027647A1 *

Also Published As

Publication number Publication date
CN112654605B (en) 2022-11-22
KR20220046593A (en) 2022-04-14
TW202115036A (en) 2021-04-16
AU2020328707A1 (en) 2022-02-24
CA3144420A1 (en) 2021-02-18
CN112654605A (en) 2021-04-13
WO2021027647A1 (en) 2021-02-18
JP2022543690A (en) 2022-10-13
EP4011865A1 (en) 2022-06-15
US20220348572A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
EP3972967A4 (en) Heterocyclic compounds, preparation methods and uses thereof
EP4077311A4 (en) Heterocyclic compounds, preparation methods and uses thereof
EP3875458A4 (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3889154A4 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
EP3539963A4 (en) Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
EP3835296A4 (en) Ketoamide compound and preparation method, pharmaceutical composition, and use thereof
EP4011886A4 (en) Tetracyclic compound, preparation method therefor and use thereof
EP3991731A4 (en) Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3424928A4 (en) Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
EP3804847A4 (en) Stable cerium-zirconium solid solution, preparation method therefor and use thereof
EP3580208A4 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP3640248A4 (en) Aminopyrimidine compound, preparation method therefor and use thereof
EP4008719A4 (en) Pyrazolone and pyrimidine compound, and preparation method and use therefor
EP3424929A4 (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
EP4039687A4 (en) Tetracyclic pyrimidinone compound, preparation method therefor, and composition and use thereof
EP3670511A4 (en) Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition
EP3556761A4 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
EP4082534A4 (en) Solid preparation, and preparation method therefor and use thereof
EP3715342A4 (en) Fluorosulfonyl-containing compound, intermediate thereof, preparation method therefor and use thereof
EP3643311A4 (en) 4-oxo-alkylated tetramic acid compound, preparation method therefor and use thereof
EP3990445A4 (en) Heterocyclic compounds, preparation methods therefor, and methods of uses thereof
EP3693358A4 (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
EP4023659A4 (en) Compound and drug conjugate, and preparation method and use thereof
EP3929198A4 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220929

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/506 20060101ALI20220923BHEP

Ipc: A61P 37/00 20060101ALI20220923BHEP

Ipc: A61P 35/00 20060101ALI20220923BHEP

Ipc: C07D 471/08 20060101AFI20220923BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)